Novel Biomarkers for Cardiovascular Risk in Obese Patients

Alexander E Berezin


Obesity remains a leading cause of cardiovascular (CV) events and diabetes worldwide. Although there are at least two main body-size phenotypes (metabolically healthy and metabolically non-healthy) of individuals with established obesity, the cardiometabolic risk amongst these patients’ populations extremely distinguishes. The editorial is discussed the controversies regarding obese paradox and the probabilities to stratify the patients with established obesity in cardiometabolic risk. It is suggested that the biomarkers could predict CV events in patients depending on obese phenotypes. The role of metabolic biomarkers, progenitor cells, natriuretic peptides, inflammatory cytokines and galectin-3 are discussed.


Obese; Metabolically healthy obese; Cardiovascular risk; Stratification; Endothelial progenitor cells

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.